Wells Fargo & Company C4 Therapeutics, Inc. Transaction History

Wells Fargo & Company

$468 Billion
Q2 2025

A detailed history of Wells Fargo & Company transactions in C4 Therapeutics, Inc. stock. As of the latest transaction made, Wells Fargo & Company holds 1,529 shares of CCCC stock, worth $3,424. This represents 0.0% of its overall portfolio holdings.

Number of Shares

1,529

Previous 523,619 99.71%

Holding current value

$3,424

Previous $837,000 99.76%

% of portfolio

0.0%

Previous 0.0%

18 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Aug 14, 2025	SELL	$1.1 - $1.74 $574,299 - $908,436	-522,090 Reduced 99.71%	1,529 $2,000
Q1 2025 May 13, 2025	BUY	$1.6 - $4.09 $779,700 - $1.99 Million	487,313 Added 1342.24%	523,619 $837,000
Q4 2024 Feb 12, 2025	BUY	$3.6 - $7.0 $33,800 - $65,723	9,389 Added 34.88%	36,306 $130,000
Q3 2024 Nov 13, 2024	BUY	$4.43 - $7.38 $5,121 - $8,531	1,156 Added 4.49%	26,917 $153,000
Q2 2024 Aug 13, 2024	BUY	$4.05 - $8.1 $102,882 - $205,764	25,403 Added 7095.81%	25,761 $119,000
Q1 2024 May 10, 2024	SELL	$5.3 - $11.0 $5,003 - $10,384	-944 Reduced 72.5%	358 $2,000
Q4 2023 Feb 09, 2024	BUY	$1.18 - $6.03 $1,142 - $5,837	968 Added 289.82%	1,302 $7,000
Q3 2023 Nov 13, 2023	BUY	$1.81 - $3.89 $41 - $89	23 Added 7.4%	334 $0
Q2 2023 Aug 15, 2023	SELL	$2.75 - $3.77 $19,734 - $27,053	-7,176 Reduced 95.85%	311 $0
Q1 2023 May 12, 2023	BUY	$3.1 - $9.02 $23,209 - $67,532	7,487 New	7,487 $23,000
Q3 2022 Nov 14, 2022	BUY	$8.03 - $12.77 $45,827 - $72,878	5,707 Added 1136.85%	6,209 $54,000
Q2 2022 Aug 12, 2022	SELL	$5.06 - $26.46 $92,506 - $483,741	-18,282 Reduced 97.33%	502 $4,000
Q1 2022 May 16, 2022	SELL	$19.99 - $33.23 $248,755 - $413,514	-12,444 Reduced 39.85%	18,784 $456,000
Q4 2021 Feb 14, 2022	BUY	$29.39 - $46.86 $83,820 - $133,644	2,852 Added 10.05%	31,228 $1.01 Million
Q3 2021 Nov 15, 2021	BUY	$35.91 - $50.5 $1.02 Million - $1.43 Million	28,341 Added 80974.29%	28,376 $1.27 Million
Q2 2021 Aug 16, 2021	SELL	$30.39 - $42.18 $159,365 - $221,191	-5,244 Reduced 99.34%	35 $0
Q1 2021 May 13, 2021	SELL	$31.96 - $46.5 $1.06 Million - $1.55 Million	-33,248 Reduced 86.3%	5,279 $195,000
Q4 2020 Feb 09, 2021	BUY	$22.8 - $37.05 $878,415 - $1.43 Million	38,527 New	38,527 $1.28 Million

Others Institutions Holding CCCC

# of Institutions

109

Shares Held

61.6M

Call Options Held

18.8K

Put Options Held

View Full List

About C4 Therapeutics, Inc.

Ticker CCCC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 48,913,800
Market Cap $110M
Description
C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 trial targeting ...

More about CCCC

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Wells Fargo & Company, based on Form 13F filings with the SEC.

News

Stay updated on Wells Fargo & Company with notifications on news.

Account

Wells Fargo & Company C4 Therapeutics, Inc. Transaction History